Document Detail

Endothelial NOS (NOS3) impairs myocardial function in developing sepsis.
Jump to Full Text
MedLine Citation:
PMID:  23397596     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Endothelial nitric oxide synthase (NOS)3-derived nitric oxide (NO) modulates inotropic response and diastolic interval for optimal cardiac performance under non-inflammatory conditions. In sepsis, excessive NO production plays a key role in severe hypotension and myocardial dysfunction. We aimed to determine the role of NOS3 on myocardial performance, NO production, and time course of sepsis development. NOS3(-/-) and C57BL/6 wildtype mice were rendered septic by cecum ligation and puncture (CLP). Cardiac function was analyzed by serial echocardiography, in vivo pressure and isolated heart measurements. Cardiac output (CO) increased to 160 % of baseline at 10 h after sepsis induction followed by a decline to 63 % of baseline after 18 h in wildtype mice. CO was unaltered in septic NOS3(-/-) mice. Despite the hyperdynamic state, cardiac function and mean arterial pressure were impaired in septic wildtype as early as 6 h post CLP. At 12 h, cardiac function in septic wildtype was refractory to catecholamines in vivo and respective isolated hearts showed impaired pressure development and limited coronary flow reserve. Hemodynamics remained stable in NOS3(-/-) mice leading to significant survival benefit. Unselective NOS inhibition in septic NOS3(-/-) mice diminished this survival benefit. Plasma NO( x )- and local myocardial NO( x )- and NO levels (via NO spin trapping) demonstrated enhanced NO( x )- and bioactive NO levels in septic wildtype as compared to NOS3(-/-) mice. Significant contribution by inducible NOS (NOS2) during this early phase of sepsis was excluded. Our data suggest that NOS3 relevantly contributes to bioactive NO pool in developing sepsis resulting in impaired cardiac contractility.
Authors:
Annette M van de Sandt; Rainer Windler; Axel Gödecke; Jan Ohlig; Simone Zander; Michael Reinartz; Jürgen Graf; Ernst E van Faassen; Tienush Rassaf; Jürgen Schrader; Malte Kelm; Marc W Merx
Related Documents :
23192916 - Cardiovascular protection and antioxidant activity of the extracts from the mycelia of ...
23220996 - Reduced coronary blood flow in cardiac tamponade: mystery solved.
19833256 - Revascularization for unprotected left main disease: evolution of the evidence basis to...
23697636 - Evaluation of tissue doppler-derived myocardial performance index in fetuses with intra...
12975406 - Qrs duration: a simple marker for predicting cardiac mortality in icd patients with hea...
4052726 - Effects of a combination of metoprolol and dazmegrel on myocardial infarct size in rats.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-02-10
Journal Detail:
Title:  Basic research in cardiology     Volume:  108     ISSN:  1435-1803     ISO Abbreviation:  Basic Res. Cardiol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-11     Completed Date:  2013-07-18     Revised Date:  2014-08-20    
Medline Journal Info:
Nlm Unique ID:  0360342     Medline TA:  Basic Res Cardiol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  330     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arterial Pressure / physiology
Cardiac Output / physiology
Cardiomyopathies / enzymology*,  physiopathology
Coronary Circulation / physiology
Disease Models, Animal*
Echocardiography
Fluorescent Antibody Technique, Indirect
Heart Function Tests
Hemodynamics / physiology*
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Nitrates / metabolism
Nitric Oxide / blood,  metabolism
Nitric Oxide Synthase Type III / physiology*
Nitrites / metabolism
Real-Time Polymerase Chain Reaction
Sepsis / enzymology*,  physiopathology
Chemical
Reg. No./Substance:
0/Nitrates; 0/Nitrites; 31C4KY9ESH/Nitric Oxide; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 1.14.13.39/Nos3 protein, mouse
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Basic Res Cardiol
Journal ID (iso-abbrev): Basic Res. Cardiol
ISSN: 0300-8428
ISSN: 1435-1803
Publisher: Springer-Verlag, Berlin/Heidelberg
Article Information
Download PDF
© The Author(s) 2013
OpenAccess:
Received Day: 24 Month: 6 Year: 2012
Revision Received Day: 7 Month: 12 Year: 2012
Accepted Day: 14 Month: 1 Year: 2013
Electronic publication date: Day: 10 Month: 2 Year: 2013
pmc-release publication date: Day: 10 Month: 2 Year: 2013
Print publication date: Month: 3 Year: 2013
Volume: 108 Issue: 2
E-location ID: 330
PubMed Id: 23397596
ID: 3597270
Publisher Id: 330
DOI: 10.1007/s00395-013-0330-8

Endothelial NOS (NOS3) impairs myocardial function in developing sepsis
Annette M. van de SandtAff1
Rainer WindlerAff1
Axel GödeckeAff2
Jan OhligAff1
Simone ZanderAff1
Michael ReinartzAff2
Jürgen GrafAff3Aff4
Ernst E. van FaassenAff5
Tienush RassafAff1
Jürgen SchraderAff6
Malte KelmAff1
Marc W. MerxAff1 Address: +49-211-8118801 +49-211-8118812 marc.merx@med.uni-duesseldorf.de
Division of Cardiology, Pneumology and Angiology, Department of Medicine, University Hospital Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany
Department of Cardiovascular Physiology, Heinrich-Heine-University, Düsseldorf, Germany
Aero Medical Center, Deutsche Lufthansa AG, Frankfurt, Germany
Medical School, Philipps-University Marburg, Marburg, Germany
Department of Nephrology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands
Department of Molecular Cardiology, Heinrich-Heine-University, Düsseldorf, Germany

Introduction

In the cardiovascular system, the signaling molecule nitric oxide (NO) has a crucial role in maintaining cardiac performance. Endothelial nitric oxide synthase (eNOS/NOS3) has been identified as the sole NOS isoform participating in mechanosensitive regulation of cardiac function. Under normoxic and non-inflammatory conditions NOS3-derived NO has a positive inotropic and lusitropic effect optimizing cardiac performance and filling (for review see [2, 22]). In the heart, NOS3 is not only expressed in endothelial cells, but also in cardiac myocytes, where it is localized at the peripheral plasmalemma and in t-tubules, in close opposition to the sarcoplasmatic reticulum. Here, it participates in regulation of myocardial metabolism [40] and contractility [49] (for review see also: [2, 22]). Positive inotropic effects of NO at lower concentrations are followed by a negative effect at higher concentrations [33, 53]. NO induced contractile dysfunction is paralleled by a reduction in myocardial energy status [33, 53]. NO is also part of signal transduction of TNF-α in different cardiac diseases [15, 66, 68, 75]. In the setting of myocardial ischemia/reperfusion injury endogenous NO contributes to hibernation [27] and myocardial NOS3 transfection attenuates ischemia/reperfusion injury [63]. Increased cardiac interstitial NO production could be observed during early ischemia and early reperfusion [58], which is in part derived from activated NOS isoforms [19, 25].

In sepsis, excessive production of NO is an important player during hypotension and catecholamine-resistant septic shock [12] and contributes to myocardial dysfunction [45].

Sepsis is the leading cause of death in critically ill patients [30] and severe hypotension and myocardial dysfunction are well-recognized manifestations of organ dysfunction in sepsis [56]. The presence of cardiovascular dysfunction in sepsis is associated with a significantly increased mortality rate of 70–90 % as compared to 20 % in septic patients without cardiovascular impairment [8]. Septic cardiomyopathy is characterized by reversible biventricular dilatation, decreased ejection fraction, and impaired response to fluid resuscitation and catecholamine stimulation [35, 45, 56]. Following the observation that serum from septic patients decreases myocyte contractile function, a number of circulating factors has been studied extensively, indicating myocardial depressant mediators including NO [36, 39, 45].

The inducible NOS (iNOS/NOS2) is generally believed to be the high-capacity NO-producing enzyme in sepsis. NOS2 is expressed in the myocardium [50] and in many other organs on demand and requires several hours to be activated (for review see [23]).

The balance between NOS3 (eNOS) and NOS2 (iNOS) has been the subject of several in vivo studies, showing that endotoxins and cytokines stimulate NOS2 expression, but decrease NOS3 activity (for review see [41]). Cardiomyocyte-specific overexpression of eNOS prevented myocardial dysfunction and death after sepsis induction [31] and eNOS−/− aggravated myocardial dysfunction in the late phase of sepsis [3]. These findings are contradicted by evidence postulating a proinflammatory role for NOS3: it has been demonstrated that NOS3-derived NO plays a crucial role in facilitating NOS2 expression in an in vivo model of endotoxemia, which was reflected by a more stable hemodynamic profile in eNOS−/− mice [7]. eNOS-derived NO exhibited proinflammatory characteristics and contributed to dysfunction of cerebrovascular endothelial cells during early onset of sepsis [21]. On the vascular level, blockade of eNOS activation suppressed LPS-induced iNOS-expression in isolated aortic rings [72].

Given this controversy concerning a proinflammatory role of NOS3 and that NO is intricately involved in regulating cardiovascular function [74], the present study aims to elucidate the influence of NOS3 on myocardial function in sepsis development.


Methods
Sepsis induction and unselective NOS inhibition

Male NOS3−/− and C57BL/6 wildtype (WT) mice were rendered septic by cecum ligation and puncture (CLP) [43, 44]. Anesthesia was induced by intraperitoneal (i.p.) administration of ketamine (60 μg/g body weight (BW)) and xylazine (10 μg/g BW). Through a 1-cm abdominal midline incision, the cecum was ligated below the ileo-cecal valve with careful attention to avoid obstruction of the ileum or colon. The cecum was then subjected to a single “through and through” perforation with a 20-gauge needle. After repositioning of the bowel, the abdominal incision was closed in layers with standard silk surgical suture 4-0 (Ethicon, Somerville, NJ, USA). Sham-operated mice underwent the same procedure except for ligation and perforation of the cecum. Animals were handled in compliance with federal regulations, the local ethical committee and the state animal welfare commission. Pain medication (buphrenorphine 0.05 mg/kg BW; Temgesic®, Essex Pharma, Grünenthal, Germany) and volume support (NaCl 0.9 %, 0.05 ml/g BW) were administered subcutaneously immediately after sepsis induction and every 8 h thereafter. All mice had unlimited access to food and water. Bacteriologic evaluation of blood and peritoneal lavage fluid obtained at 12 h after CLP confirmed bacterial peritonitis and bacteremia in WT and NOS3−/− mice, whereas no pathogens could be cultured out of blood drawn from sham-operated mice. The pathogens identified were Escherichia coli, Diplococcus, and Staphylococcus xylosus. To achieve unselective NOS inhibition in a subset of the studied animals, osmotic mini pumps secreting S-ethylisothiourea (370 μg/h) (ETU) were placed into the peritoneal cavity immediately following sepsis induction.

Echocardiography

Conscious mice were examined by serial echocardiography [43, 44]. Employing a 15-MHz linear transducer connected to a Sonos 5500™ (Phillips Medical Systems; frequency fusion: 5; interrogation depth 2 cm), the heart was imaged in two-dimensional (2D) mode in the parasternal long axis view and 2D guided M-mode images were obtained at the aortic root for offline aortic diameter measurements. Aortic flow velocity was measured with pulsed-wave Doppler. The reference volume was placed just above the aortic root with careful angle-adjustment strictly parallel to the ascending aorta. Cardiac output was computed from aortic flow velocity time integral, aortic root diameter, and heart rate.

In vivo hemodynamic measurements

6 and 12 h post-CLP, invasive hemodynamics were assessed using a 1.4F Millar pressure catheter (SPR-839, Millar Instrument, Houston, TX, USA) placed into the left ventricle through the right carotid artery. Pressure data were analyzed with dedicated software (IOX, EMKA, Paris, France) to calculate left-ventricular developed pressure (LVDP), and the first derivatives of left intraventricular pressure (rate of pressure development +dP/dtmax and rate of pressure decrease −dP/dtmin). For catecholamine responsiveness, norepinephrine was administered at 0.4 μg/kg/min, i.p. Mean arterial blood pressure was measured in the aorta ascendens.

Langendorff setup

For isolated heart measurements murine hearts were taken at 6 and 12 h post-CLP, and mounted with retrograde perfusion at 100 mmHg constant pressure with modified Krebs–Henseleit buffer in an isolated heart apparatus (Hugo Sachs Elektronik), as previously described [13, 4244]. In brief, mice were anesthetized and injected with 250 IU heparin i.p.. The hearts were rapidly excised and transferred for preparation of the aortic arch to oxygenated Krebs–Henseleit buffer. The aorta was cannulated, and hearts were perfused at 100 mmHg constant pressure with modified Krebs–Henseleit buffer containing (in mM) NaCl 116, KCl 4.6, MgSO4 1.1, NaHCO3 24.9, CaCl2 2.5, KH2PO4 1.2, glucose 8.3, pyruvate 2.0 and EDTA 0.5, equilibrated with 95 % O2 and 5 % CO2 (pH 7.4, 37 °C). A home-made fluid-filled polyethylene balloon was inserted into the left ventricle and connected via a fluid-filled polyethylene tubing to a further pressure transducer. Left ventricular end-diastolic pressure was set at 5 mmHg. Hearts were stimulated at 600 beats per minute and were allowed to stabilize for 20 min at 100 mg constant perfusion pressure prior to data acquisition. Left ventricular pressure (LVP), perfusion pressure, aortic flow, and heart rate were measured continuously using a personal computer with analog–digital converter (2,000 Hz) and dedicated software (EMKA Technologies, Paris, France). Derivative parameters (dP/dtmax, dP/dtmin, coronary flow) were displayed in real time and recorded. Bradykinin and adenosine were infused into the aortic cannula at a concentration of 5 and 1 μmol, respectively.

Measurement of nitrite/nitrate in plasma and heart tissue

Blood samples were collected by intracardiac puncture at baseline, 6 and 12 h after sepsis induction. Blood and tissue samples were prepared for determination of nitrate and nitrite [52]. Blood samples were centrifuged and plasma was aspirated and stored at −80 °C. To perform analysis, frozen plasma was thawed and mixed with methanol (1:1, v/v) to precipitate the proteins. Samples were centrifuged again and a NOx-analyzing system (ENO-20 Analyzer, EICOM Corp., Kyoto, Japan) was used to analyze the supernatant. The high-pressure liquid chromatography (HPLC) technique is a highly sensitive technique for measurement of nitrite and nitrate. This method employs ion chromatography with online reduction of nitrate to nitrite and subsequent postcolumn derivatization with the Griess reagent. The detection limit for nitrite and nitrate is 1 nmol/l for either anion at an injection volume of 100 μl [18, 26, 34, 51]. The high validity has been shown as compared to other highly sensitive and specific techniques such as chemiluminescence detection. After thoracotomy, a cannula was inserted into the heart and the heart was flushed free of blood by in situ perfusion with NaCl supplemented with N-ethylmaleimide (NEM)/EDTA (100/2.5 mM) at a rate of 10 ml/min. After perfusion, hearts were excised from the mice, snap frozen in liquid nitrogen and homogenized immediately in ice-cold N-ethylmaleimide/EDTA-containing perfusion buffer by using a Schuett homogenplus semi automatic glass-on-glass-homogenizer and kept on ice. For determination of nitrite and nitrate (after reaction with nitrate reductase) in biological tissues reductive gas phase chemiluminescence (CLD, Model 77am sp or Model 88am, Eco Physics; Duernten, Switzerland) was used.

Detection of NO radicals in heart tissue

Local NO levels in murine heart tissue were detected by spin trapping with iron–dithiocarbamate complexes which is one of the most specific methods for NO detection in biological tissue. Na2+-DETC was injected intraperitoneally and Fe2+-citrate subcutaneously into the scruff of the neck, respectively with final dosages of 500 mg sodium DETC/kg; 35 mg FeSO4/kg and 190 mg sodium citrate/kg. The application of iron–dithiocarbamate complexes as spin trap is motivated by their high affinity to bind nitric oxide radicals. Applied spin-trapping reagents react with free radicals to form relatively stable radical adducts that can be detect by EPR spectroscopy. Iron–nitrosyl complexes were generated in cardiac tissue itself: upon their formation the Fe–DETC complexes, being insoluble, remain immobilized in the apolar compartments of the tissues so that the tissue adduct yields of MNIC reflect the local levels of bioavailable NO in that particular tissue type [69, 71]. The NO trapping proceeded for 30 min before sacrifice of the animals. The hearts were excised, incubated in strong HEPES buffer (150 mM, pH 7.4), snap frozen in liquid nitrogen and stored at 77 K. After reduction with dithionite EPR spectra were taken at 77 K on a Bruker ESP300E spectrometer, as described previously [69, 70]. The yields of NO–Fe2+–DETC complexes were quantified by comparing with frozen reference solutions of NO–Fe2+–MGD in PBS buffer.

RNA extraction and quantitative RT-PCR analysis

Total RNA was extracted from mouse hearts using “RNeasy® fibrous tissue kit” (Qiagen). Total RNA (1 μg per sample) was reverse-transcribed, and real-time PCR was performed in triplicate using the Applied Biosystems 7300 Fast Real-time PCR system and TaqMan® GenExpression Assays (Applied Biosystems) for NOS3 (nitric oxide synthase 3, endothelial; Mm00435217_m1), NOS2 (nitric oxide synthase 2, inducible; Mm00440502_m1), NOS1 (nitric oxide synthase 1, neuronal; Mm00435175_m1), TNF-α (tumor necrosis factor; Mm00443258_m1), interleukin-6 (Mm00446190_m1) and GAPDH as endogenous control (glyceraldehyde-3-phosphate dehydrogenase; Mm99999915_g1). The setup of reaction consisted of 1 μl of cDNA (10 ng), 1 μl of TaqMan primer set, 10 μl Taq [TaqMan® Gen Expression Master Mix (2×); no. 4369016], and 8 μl of H2O. PCR was performed according to manufacturer’s instructions (standard run type).

Immunohistochemistry and blood cell count

Heart samples were fixed in 4 % formaldehyde phosphate buffer, dehydrated and paraffin-embedded. Serial sections (3 per mouse, 400 μm apart) were stained to analyze the heart tissue for the content of neutrophils (Naphthol AS-D Chloroacetate kit, Sigma), monocytes (α-Naphthyl Acetate kit, Sigma) and lymphocytes (CD3 (Serotec), Universal Strepavidin FITC, Vectors Laboratories and Biotinylated Anti-Mouse/Rabbit/Goat IgG, Vectors Laboratories). Cells were numbered in six different fields per section (cells/mm2). For 3-nitrotyrosine detection serial sections were incubated with a polyclonal antibody against nitrotyrosine (USBiological, N2700-06), followed by sheep anti-rabbit IgG conjugated to FITC (Rockland, 611-641-122).

Statistical analysis

The results are given as mean ± SD. For repeated measurements, data were analyzed by two-way ANOVA followed by Bonferroni’s post hoc test. Otherwise, an unpaired Student’s t test was applied. p < 0.05 was set as the threshold of significance. Kaplan–Meier survival curves were compared using a log-rank test to determine significance. Myocardial gene expression was analyzed by REST 2009 software (Qiagen).


Results
Survival after CLP is profoundly prolonged in NOS3−/− mice

No deaths occurred in the sham-operated group in both strains. The survival curves for septic mice clearly attest to the prolonged survival in NOS3−/− mice with median survival extended to 70 h from 29 h in WT mice (Fig. 1a). Unselective NOS inhibition with ethylthiourea (ETU) in NOS3−/− mice after sepsis induction diminished this survival benefit, with only a discreet improvement in survival time remaining (mean survival = 38 h, n = 12, p < 0.05). In contrast to this finding, ETU application in WT mice after CLP led to slight improvement in survival time (mean survival = 31 h, n = 12 per group, p < 0.05).

NOS3 induces a hyperdynamic state despite impaired cardiac function

To address possible changes in cardiac output secondary to sepsis, we studied conscious mice by echocardiography at baseline and every 2 h after sepsis induction (CLP) or sham operation for a total of 24 h. As depicted in Fig. 1b, cardiac output (CO) decreased in all groups during the first 4 h post surgery most likely due to the effects of anesthesia. After recovery from surgery, CO began to increase above baseline values in WT animals subjected to CLP. This increase observed in septic WT mice amounted to a maximum of 160 % of baseline at 10 h after CLP. This hyperdynamic phase was followed by a steady decline in CO, which decreased to values below baseline after 16 h without signs of recuperation. In contrast (subsequent to the first 4 postoperative hours), CO remained stable and unaltered as compared to baseline during the observation period in septic NOS3−/− mice as well as in all sham-operated animals (Fig. 1b). Unselective NOS inhibition led to stable and unaltered cardiac output in septic WT mice without a hyperdynamic phase while having no effect on cardiac output in septic NOS3−/− mice. Corresponding to the beginning of the hyperdynamic phase at 6 h after CLP, cardiac function was additionally assessed invasively using a pressure catheter. At this time point, septic WT mice demonstrated a significant increase in heart rate (WT baseline: heart rate = 547.6 ± 47.3 beats/min; WT CLP 6 h: heart rate = 603.7 ± 26.1 beats/min; WT baseline vs. WT CLP 6 h = *p < 0.05; Fig. 2a), whereas heart rate remained stable in NOS3−/− mice (NOS3−/− baseline: heart rate = 492.5 ± 51.5 beats/min; NOS3−/− CLP 6 h: heart rate = 508.0 ± 47.2 beats/min, NOS3−/− baseline vs. NOS3−/− CLP 6 h = n.s.). Despite the high CO assessed by echocardiography at 6 h post CLP, WT mice exhibited impaired left ventricular function with diminished LVDP and +dP/dtmax as well as impaired −dP/dtmin as compared to animals at baseline (Fig. 2b–d). In contrast, there was no deterioration in LV function detected in septic NOS3−/− mice. With respect to norepinephrine responsiveness, WT mice responded to catecholamine application at 6 h after sepsis induction with increased CO, brought about by an increase in heart rate (Fig. 2e–h). At 12 h post CLP septic WT remained refractory to norepinephrine stimulation with unaltered LVDP, +dP/dtmax and −dP/dtmin while these parameters increased in NOS3−/− mice to an extent comparable to animals at baseline (Fig. 2e–h). When compared with baseline and NOS3−/− mice, mean arterial blood pressure was diminished in septic WT at 6 h after sepsis induction (Fig. 3a). Systemic vascular resistance was estimated from the median mean arterial blood pressure and median cardiac output (Fig. 3b). Although septic WT mice developed a progressive drop in systemic vascular resistance (WT baseline vs. WT CLP 6 h: −34.6 %; WT baseline vs. WT CLP 12 h: −40.5 %) systemic vascular resistance remained stable in NOS3−/− mice (NOS3−/− baseline vs. NOS3−/− CLP 6 h: −9.2 %, NOS3−/− baseline vs. NOS3−/− CLP 12 h: +1.3 %). Although the profoundly reduced vascular resistance in WT took center stage in the initial phase of sepsis (6 h), myocardial dysfunction was evident at 12 h after sepsis induction with impaired LVDP, +dP/dtmax and −dP/dtmin in isolated hearts of septic WT mice. Again, we observed no significant deterioration in cardiac function in isolated hearts of septic NOS3−/− compared to baseline (Fig. 4a–c).

NOS3 impairs coronary flow reserve

Coronary flow was increased by 30 % in WT CLP mice as compared to WT mice. No significant difference was detected in coronary flow between septic NOS3−/− and non-septic NOS3−/− animals. Susceptibility to NOS3 stimulation by bradykinin was approximately twice as pronounced in WT CLP mice as compared to non-septic mice, indicating a high level of NOS3 activation secondary to sepsis (Fig. 5a, b). As expected, bradykinin stimulation had no effect in NOS3−/− hearts. Coronary flow reserve measured after adenosine application exhibited the opposite pattern, being diminished in septic WT mice as compared to baseline, while hearts from septic NOS3−/− mice showed close to twofold augmentation of coronary flow similar to the baseline observations (Fig. 5a, b).

NOS3 contributes to bioactive NO pool

NO has a short half life of a few ms in vivo, making direct measurement a challenging task in plasma and tissues. Plasma concentrations of downstream metabolites like nitrate and nitrite have been used as proxies for NO proper [47]. Plasma nitrate and nitrite levels were measured at baseline, 6 and 12 h post-CLP using a [\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$${\text{NO}}_{x^-}$$\end{document}] analyzing system. When compared with plasma nitrate levels at baseline, septic WT mice exhibited increased nitrate levels at 6 h after sepsis induction (Fig. 6a). Septic NOS3−/− mice showed a lesser increase in nitrate levels, with baseline values being significantly reduced as compared to WT mice, likely due to the absence of NOS3. Similarly to nitrate plasma levels (Fig. 6a), nitrate increased significantly at 6 h after sepsis induction in the heart tissue of septic WT mice. In contrast, in septic NOS3−/− hearts, we observed a lesser increase in nitrate levels with no significant changes compared to baseline at 6 h post CLP (Fig. 6b). During further progress of sepsis nitrate levels in plasma and heart tissue decreased in septic WT mice. Nitrite levels in plasma and heart tissue were found to be comparable over time and in both strains (data not shown). We used NO spin trapping and EPR to quantify the in vivo NO levels in heart tissue. After in vivo spin trapping with Fe–DETC complexes, EPR spectroscopy of frozen heart tissue showed the characteristic triplet spectrum of ferrous mononitrosyl iron complexes [MNIC, NO–Fe2+–(DETC)2] in the hearts of NOS3−/− and WT mice. At 6 h post-CLP, the cardiac tissues of septic WT and NOS3−/− mice displayed higher MNIC yields compared to animals at baseline, while the heart tissue of septic NOS3−/− mutants contained significantly lower MNIC concentrations than those of septic WT mice. WT and NOS3−/− mice had significantly lower and comparable yields at baseline (Fig. 6c). Immunohistochemical staining demonstrated an increase of nitrotyrosine in heart tissue of septic WT mice at 6 h post CLP, whereas no differences could be detected in NOS3−/− mice (see Online Resource Figure 1 in the online supplement). Quantitative RT-PCR analysis of NOS2- and NOS3-expression in the hearts at baseline, 6 and 12 h after sepsis induction revealed neither increase in NOS2- nor NOS3-expression in septic WT and NOS3−/− mice compared to baseline (see Online Resource Figure 2a, b). There was no difference detected between both strains. In addition, we analyzed protein expression of NOS3, NOS2, and neuronal NOS (NOS1) in heart tissues. When compared with baseline, NOS3 expression did not differ in septic WT mice at 6 and 12 h post CLP. As it would be expected, western blot revealed the absence of NOS3 (eNOS) protein in NOS3−/− mice [16] (see Online Resource Figure 2c, d). Cardiac protein expression of NOS2 and NOS1 always remained below detection levels in both strains. Determination of phospho-NOS3 revealed no increase in WT mice during sepsis development (see Online Resource Figure 2e). Furthermore, global protein glutathionylation [55] was not increased in hearts of septic mice and signal intensity remained constant at the level of NOS3 suggesting no increase in NOS3 glutathionylation in septic WT mice (see Online Resource Figure 3). There were no signs of increased ROS production in the latter (see Online Resource Figure 4).

Myocardial inflammatory response

CLP promoted invasion of the myocardium by inflammatory cells (neutrophils, monocytes and lymphocytes) in septic WT and NOS3−/− mice. When compared with septic WT mice the myocardial infiltration with neutrophils and monocytes in NOS3−/− mice was less severe than in WT mice at 12 h post CLP (Table 1). Blood cell count demonstrated a progressive reduction in white blood cell counts in both strains. We further examined the expression levels of genes encoding inflammatory cytokines in the heart at 6 and 12 h after CLP. Levels of TNF-α and IL-6 were increased already at 6 h after sepsis induction in both genotypes.


Discussion

The main finding of the present study is that endothelial NOS (eNOS/NOS3) plays a key role in the development of sepsis. NOS3 facilitates a drop in mean arterial blood pressure and systemic vascular resistance. Furthermore, we observed a hyperdynamic state despite impaired left ventricular function followed by rapid deterioration of cardiac output (CO) and limited coronary flow reserve, leading to short survival times. In contrast, septic NOS3−/− mice display stable blood pressure, preserved coronary flow reserve and CO with survival time extended more than twofold. As possible contributing mechanisms we demonstrate decreased endogenous NOx-levels and dampened myocardial inflammatory response in an early stage of polymicrobial sepsis.

NOS3 contributes to bioactive NO pool

That NOS3 contributes to endogenous NO production in developing sepsis is supported by our finding that NOS3−/− mice exhibited a significantly smaller increase of plasma nitrate levels compared to WT during sepsis development. In concordance with our findings, LPS-treatment of WT mice resulted in a profound elevation of plasma NOx measurements [7, 72]. This response to LPS in WT was twice as pronounced compared to the increase observed in eNOS−/− animals [7, 72]. In patients who develop septic shock, plasma NOx levels and NOx concentrations are higher in non-survivors [28]. As a consequence of significantly enhanced endogenous NO production we observed a reduced sensitivity to the NO donor SNP in isolated aortic rings from septic WT mice (see Online Resource Figure 5a). In concordance with our results, relaxation response to NO donors in aortic rings was suppressed in LPS-treated WT mice and unaffected in rings of eNOS−/− animals [72]. In this context, as readout for bioactive NO levels and focussing on the local NO status of cardiac tissue, we detected significantly increased myocardial MNIC yields in septic WT mice compared to septic NOS3−/− animals.

Despite increased endogenous NO production, we did not observe an increase in NOS1-, NOS2-, NOS3-mRNA, as well as NOS1-, NOS2-, NOS3- and phospho-NOS3-protein expression in developing sepsis (Online Resource Figure 2). However, direct evidence for a high level of NOS3 activation is provided by our studies of the septic coronary vasculature, in which baseline flow and response to NOS3 stimulation were markedly increased and coronary flow reserve reduced by a third. No alterations in coronary flow were noted in NOS3−/− mice. An increased eNOS activity has been demonstrated in the initial phase of sepsis [37], followed by induction of iNOS in the later phase [67]. A further study revealed a maximum of iNOS-protein content at 24 h after CLP [11]. In an ovine sepsis model, total NOS increased at 12 and 24 h after injury, whereas iNOS activity was not altered significantly [37]. This was accompanied by an early increase of 3-nitrotyrosine, a marker of protein nitration [37] suggesting that constitutive NOS (NOS3 and NOS1) is the main contributor to increased NO levels in this model. In concordance with this finding, we also detected augmented 3-nitrotyrosine levels in septic WT mice at 6 h after sepsis induction (Online Resource 1). It is known that increased nitrotyrosine formation during sepsis may uncouple NOS3 activity and increase oxidative stress [65]. Superoxide produced by NADPH oxidase, which is considered to be a major source of ROS that are implicated in the pathophysiology of many cardiovascular diseases [59, 76], may react with NO, thereby generating peroxynitrite. The latter is considered to induce delayed and irreversible cardiac damage [57]. In pressure-overloaded ischemic-reperfused hearts, increased nitrosative and oxidative stress contributes to the exacerbating impact of pressure-overload on MPT pore opening and cell death [46]. NOS3 itself can be a superoxide source, thereby causing endothelial dysfunction [14]. Endothelial dysfunction, a key contributor to organ failure and death in sepsis [1, 9], is also clearly visible in septic wildtype mice (Online Resource Figure 5b). In our present study, cardiac tissue of septic wildtype mice displayed no evidence for increased global protein glutathionylation (Online Resource Figure 3) or ROS generation (Online Resource Figure 4) in early sepsis suggesting that the observed hemodynamic alterations are primarily due to increased bioactive NO and nitrosative stress in this early stage of sepsis development.

NOS3 impairs cardiovascular function in developing sepsis

The observed hemodynamic alterations in our study are typically found also in septic patients, namely a hyperdynamic followed by a hypodynamic state (Fig. 1b). A prominent feature in this context is the reduced vascular tone and vasodilatation in developing sepsis. In concordance, we demonstrate a drop in mean arterial blood pressure and systemic vascular resistance in septic wildtype (WT) mice at 6 h after sepsis induction. The inducible NOS (iNOS/NOS2) is generally believed to be responsible for the hypotension and loss of vascular tone in ongoing sepsis. After LPS treatment, a drop in blood pressure is commonly observed in WT mice, but absent in iNOS−/− mice [20]. Selective inhibitors of iNOS increased mean arterial blood pressure [32] and abrogated LPS-induced loss of vascular tone [60]. Thus, NOS2 appears to be crucial in hypotension in LPS-induced sepsis. In this context, the stable mean arterial blood pressure and systemic vascular resistance in septic NOS3−/− as compared to WT mice observed in the present study might appear unexpected. NOS3-derived NO plays an important role in the regulation of regional vascular tone and blood flow and the constant, low rate of NO production by constitutive NOS forms can be increased acutely as part of the acute inflammatory response [23]. In addition, the activity of NOS3 is required for the induction of NOS2: a temporal reduction in iNOS expression and activity could be demonstrated in LPS-treated septic eNOS−/− mice [7]. Similar to our results, a stable blood pressure profile of eNOS−/− mice has been described during endotoxemia [7]. Following LPS infusion, a markedly increased myocardial eNOS activity has been demonstrated leading to a decrease in blood pressure after 30 min [10]. Concurrent with stable blood pressure and systemic vascular resistance, NOS3−/− mice exhibited preserved LVDP, +dP/dtmax and −dP/dtmin while cardiac function was impaired in septic WT mice already at 6 h after sepsis induction. This time point corresponded to the beginning of the hyperdynamic phase in WT mice. This suggests that the cardiac output increase in septic WT mice is predominantly related to the profoundly reduced systemic vascular resistance due to sepsis-induced vasodilatation and obscures myocardial dysfunction [45], which subsequently becomes evident.

Cardiac function of isolated hearts from septic WT mice was compromised with impaired LVDP, +dP/dtmax and −dP/dtmin at 12 h after sepsis induction. This time point in sepsis development was also characterized by refractoriness to norepinephrine stimulation in vivo. Thus, in this phase of ongoing sepsis, decreased cardiac output may reflect direct myocardial depression. Deviating from this pattern well known from several forms of human sepsis [45, 48], septic NOS3−/− mice exhibited stable CO and preserved cardiac function. NOS3 is considered to be the major isoform in the healthy heart and is expressed in vascular endothelium and cardiac myocytes [2]. It has been suggested that local NO levels in cardiac tissue are important modulators of cardiac contractility, and that high NO levels induce cardiac depression [33, 53]. Increased NOS3-expression in ventricular myocardium of failing human hearts may contribute to contractile dysfunction [61]. Hearts of mice with myocyte-specific eNOS-overexpression had reduced basal contractility that was partially reversed by NOS blockade [4].

Septic NOS3−/− mice exhibited preserved cardiac function, including responsiveness to catecholamine stimulation. When considering the well-described anti-adrenergic effect of NO in the heart [17, 54], the preserved responsiveness to catecholamine stimulation in NOS3−/− mice is probably also due to diminished endogenous NO production. In contrast to the findings from the present study, mice with cardiomyocyte-specific overexpression of eNOS were protected from myocardial dysfunction and death during endotoxemia [31]. In a recent study, septic eNOS−/− mice exhibited more marked myocardial dysfunction 22 h after sepsis induction, which equated to a late phase of sepsis in the model studied [3]. Impaired cardiac function at this time point was associated with an exaggerated inflammatory response [3]. Reasons for these discrepant findings are probably multi-factorial and depend amongst others on the sepsis model used: Although our model demonstrated a peak in TNF-α and IL-6 expression at 6 h post CLP in both strains, Bougaki et al. [3] observed an increase in TNF-α as well as IL-6 expression at 22 h after colon ascendens stent peritonitis and genetic eNOS deficiency was associated with enhanced induction of proinflammatory cytokines. In contrast to this study, a proinflammatory role of NOS3 was postulated by Connelly et al. [7]. Fitting well with initial proinflammatory effects of NOS3, we observed that WT mice exhibited a more marked myocardial infiltration with neutrophils, monocytes, and lymphocytes in the hearts at 12 h after sepsis induction. The activation and recruitment of inflammatory cells to the heart is a major early event in cardiac dysfunction promoted by septicemia [64]. Thus, dampened myocardial inflammatory response and decreased endogenous NOx levels may contribute to cardiovascular stabilization in the present model.

Interestingly, unselective NOS inhibition also led to stabilization of CO in septic WT mice. Despite stabilized CO, septic WT mice exhibited just a minor improvement in survival time after unselective NOS inhibition. This is in concordance with the conflicting and overall disappointing results obtained by unselective NOS inhibition in septic patients [5, 38]. With a large amount of data supporting a detrimental role for NOS2 in sepsis [24, 29, 62], it might be expected that NOS2 inhibition would result in additional survival benefit in NOS3−/− mice. In contrast to this expectation, our studies involving unselective NOS inhibition in NOS3−/− mice demonstrate significantly reduced survival time. iNOS2−/− mice have been shown to have decreased survival in a CLP model of sepsis [6] and decreased defense against bacterial inoculation in iNOS−/− mice has been demonstrated [73]. In conclusion, our results support that NOS3 is a major source of endogenous NO in developing sepsis leading to myocardial dysfunction.


Electronic supplementary material

Notes

A. M. van de Sandt and R. Windler contributed equally to this work.

This work was supported in part by ME1821/2-3 to MWM and ME1821/3-1 [FOR809] to MWM and MK, RA969/6-1 and RA969/7-1 to TR and KE405/5-1 to MK. We thank S. Becher and R. Taskesen for excellent technical assistance. The authors declare that they have no conflict of interest.


References
1.. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndromeBloodYear: 20031013765377710.1182/blood-2002-06-188712543869
2.. Balligand JL,Feron O,Dessy C. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissuesPhysiol RevYear: 20098948153410.1152/physrev.00042.200719342613
3.. Bougaki M,Searles RJ,Kida K,Yu J,Buys ES,Ichinose F. Nos3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsisShockYear: 20103428129010.1097/SHK.0b013e3181cdc32719997049
4.. Brunner F,Andrew P,Wölkert G,Zechner R,Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthaseCirculationYear: 20011043097310210.1161/hc5001.10196611748107
5.. Cobb JP. Nitric oxide synthase inhibition as therapy for sepsis: a decade of promiseSurg InfectYear: 200129310010.1089/109629601750469410
6.. Cobb JP, Hotchkiss R, Swanson PE et al (1999) Inducible nitric oxide synthase (iNOS) gene deficiency increases the mortality of sepsis in mice. Surgery 126:438–442. pii: N9c41cb98N2a1153cc
7.. Connelly L,Madhani M,Hobbs AJ. Resistance to endotoxic shock in endothelial nitric-oxide synthase (eNOS) knock-out mice: a pro-inflammatory role for eNOS-derived no in vivoJ Biol ChemYear: 2005280100401004610.1074/jbc.M41199120015647265
8.. Court O,Kumar A,Parrillo JE,Kumar A. Clinical review: myocardial depression in sepsis and septic shockCrit CareYear: 2002650050810.1186/cc182212493071
9.. Davis JS,Darcy CJ,Yeo TW,Jones C,McNeil YR,Stephens DP,Celermajer DS,Anstey NM. Asymmetric dimethylarginine, endothelial nitric oxide bioavailability and mortality in sepsisPLoS ONEYear: 20116e17260e1726010.1371/journal.pone.001726021364995
10.. Doursout MF,Oguchi T,Fischer UM,Liang Y,Chelly B,Hartley CJ,Chelly JE. Distribution of NOS isoforms in a porcine endotoxin shock modelShockYear: 20082969270217909454
11.. Fernandes D,Sordi R,Kramer-Pacheco LK,Nardi GM,Heckert BT,Villela CG,Lobo AR,Barja-Fidalgo C,Assreuy J. Late, but not early, inhibition of soluble guanylate cyclase decreases mortality in a rat sepsis modelJ Pharmacol Exp TherYear: 200932899199910.1124/jpet.108.14203419073910
12.. Flierl MA,Rittirsch D,Huber-Lang MS,Sarma JV,Ward PA. Molecular events in the cardiomyopathy of sepsisMol MedYear: 20081432733618256728
13.. Flögel U,Decking UK,Gödecke A,Schrader J. Contribution of NO to ischemia-reperfusion injury in the saline-perfused heart: a study in endothelial NO synthase knockout miceJ Mol Cell CardiolYear: 19993182783610.1006/jmcc.1998.092110329210
14.. Förstermann U,Münzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menaceCirculationYear: 20061131708171410.1161/CIRCULATIONAHA.105.60253216585403
15.. Garlie JB,Hamid T,Gu Y,Ismahil MA,Chandrasekar B,Prabhu SD. Tumor necrosis factor receptor 2 signaling limits ß-adrenergic receptor-mediated cardiac hypertrophy in vivoBasic Res CardiolYear: 20111061193120510.1007/s00395-011-0196-621691899
16.. Gödecke A,Decking UK,Ding Z,Hirchenhain J,Bidmon H-J,Gödecke S,Schrader J. Coronary hemodynamics in endothelial NO synthase knockout miceCirc ResYear: 19988218619410.1161/01.RES.82.2.1869468189
17.. Godecke A,Heinicke T,Kamkin A,Kiseleva I,Strasser RH,Decking UK,Stumpe T,Isenberg G,Schrader J. Inotropic response to beta-adrenergic receptor stimulation and anti-adrenergic effect of ACh in endothelial NO synthase-deficient mouse heartsJ PhysiolYear: 200153219520410.1111/j.1469-7793.2001.0195g.x11368026
18.. Grau M,Hendgen-Cotta UB,Brouzos P,Drexhage C,Rassaf T,Lauer T,Dejam A,Kelm M,Kleinbongard P. Recent methodological advances in the analysis of nitrite in the human circulation: nitrite as a biochemical parameter of the L-arginine/NO pathwayJ Chromatogr B Analyt Technol Biomed Life SciYear: 200785110612310.1016/j.jchromb.2007.02.00217344107
19.. Guo Y,Sanganalmath SK,Wu W,Zhu X,Huang Y,Tan W,Ildstad ST,Li Q,Bolli R. Identification of inducible nitric oxide synthase in peripheral blood cells as a mediator of myocardial ischemia/reperfusion injuryBasic Res CardiolYear: 201210725310.1007/s00395-012-0253-922351077
20.. Hallemeesch MM,Janssen BJA,de Jonge WJ,Soeters PB,Lamers WH,Deutz NEP. NO production by cNOS and iNOS reflects blood pressure changes in LPS-challenged miceAm J Physiol Endrocrinol MetabYear: 2003285E871E875
21.. Handa O,Stephen J,Cepinskas G. Role of endothelial nitric oxide synthase-derived nitric oxide in activation and dysfunction of cerebrovascular endothelial cells during early onsets of sepsisAm J Physiol Heart Circ PhysiolYear: 2008295H1712H171910.1152/ajpheart.00476.200818723768
22.. Hare JM,Stamler J. NO/redox disequilibrium in the failing heart and cardiovascular systemJ Clin InvestYear: 200511550951715765132
23.. Hauser B,Bracht H,Matejovic M,Radermacher P,Venkatesh B. Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studiesAnesth AnalgYear: 200510148849810.1213/01.ANE.0000177117.80058.4D16037166
24.. Heemskerk S,Masereeuw R,Russel FG,Pickkers P. Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injuryNat Rev NephrolYear: 2009562964010.1038/nrneph.2009.15519786992
25.. Heinzel FR,Gres P,Boengler K,Duschin A,Konietzka I,Rassaf T,Snedovskaya J,Meyer S,Skyschally A,Kelm M,Heusch G,Schulz R. Inducible nitric oxide synthase expression and cardiomyocyte dysfunction during sustained moderate ischemia in pigsCirc ResYear: 20081031120112710.1161/CIRCRESAHA.108.18601518818404
26.. Hendgen-Cotta U,Grau M,Rassaf T,Kelm M,Kleinbongard P. Reductive gas-phase chemiluminescence and flow injection analysis for measurement of the nitric oxide pool in biological matricesMethods EnzymolYear: 200844129531510.1016/S0076-6879(08)01216-018554541
27.. Heusch G,Post H,Michel MC,Kelm M,Schulz R. Endogenous nitric oxide and myocardial adaptation to ischemiaCirc ResYear: 20008714615210.1161/01.RES.87.2.14610903999
28.. Ho JT, Chapman MJ, O′Conner S, Lam S, Edwards J, Ludbrook G, Lewis JG, Torpy DJ (2010) Characteristics of plasma NOx levels in severe sepsis: high interindividual variability and correlation with illness severity, but lack of correlation with cortisol levels. Clin Endocrinol (Oxf) 73:413–420. doi:10.1111/j.1365-2265.2010.03817.x
29.. Hollenberg SM,Broussard M,Osman J,Parrillo JE. Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthaseCirc ResYear: 20008677477810.1161/01.RES.86.7.77410764411
30.. Hotchkiss RS,Karl IE. The pathophysiology and treatment of sepsisN Engl J MedYear: 200334813815010.1056/NEJMra02133312519925
31.. Ichinose F,Buys ES,Neilan TG,Furutani EM,Morgan JG,Jassal DS,Graveline AR,Searles RJ,Lim CC,Kaneki M,Picard MH,Scherrer-Crosbie M,Janssens S,Liao R,Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shockCirc ResYear: 200710013013910.1161/01.RES.0000253888.09574.7a17138944
32.. Kadoi Y, Goto F (2004) Selective inducible nitric oxide inhibition can restore hemodynamics, but does not improve neurological dysfunction in experimentally-induced septic shock in rats. Anesth Analg 99:212–220. doi:10.1213/01ANE.0000118111.94913.22
33.. Kelm M,Schäfer S,Dahmann R,Dolu B,Perings S,Decking U,Schrader J,Strauer BE. Nitric oxide induced contractile dysfunction is related to a reduction in myocardial energy generationCardiovasc ResYear: 19973618519410.1016/S0008-6363(97)00149-19463630
34.. Kleinbongard P,Dejam A,Lauer T,Rassaf T,Schindler A,Picker O,Scheeren T,Gödecke A,Schrader J,Schulz R,Heusch G,Schaub GA,Bryan NS,Feelisch M,Kelm M. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammalsFree Radic Biol MedYear: 20033579079610.1016/S0891-5849(03)00406-414583343
35.. Kumar A,Haery C,Parrillo JE. Myocardial dysfunction in septic shock: part I. Clinical manifestation of cardiovascular dysfunctionJ Cardiothorac Vasc AnesthYear: 20011536437610.1053/jcan.2001.2231711426372
36.. Kumar A,Krieger A,Symeoneides S,Kumar A,Parrillo JE. Myocardial dysfunction in septic shock: part II. Role of cytokines and nitric oxideJ Cardiothorac Vasc AnesthYear: 20011548551110.1053/jcan.2001.2500311505357
37.. Lange M,Connelly R,Traber DL,Hamahata A,Nakano Y,Esechie A,Jonkam C,von Borzyskowski S,Traber LD,Schmalstieg FC,Herndon DN,Enkhbaatar P. Time course of nitric oxide synthases, nitrosative stress, and poly(ADP ribosylation) in an ovine sepsis modelCrit CareYear: 201014R129R12910.1186/cc909720602787
38.. Lopez A,Lorente JA,Steingrub J,Bakker J,McLuckie A,Willatts S,Brockway M,Anzueto A,Holzapfel L,Breen D,Silverman JT,Donaldson J,Arneson C,Grove G,Grossman S,Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shockCrit Care MedYear: 200432213010.1097/01.CCM.0000105581.01815.C614707556
39.. Lupia E,Spatola T,Cuccurullo A,Bosco O,Mariano F,Pucci A,Ramella R,Alloatti G,Montrucchio G. Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serumBasic Res CardiolYear: 201010560962010.1007/s00395-010-0103-620467749
40.. Martin C,Schulz R,Post H,Gres P,Heusch G. Effect of NO synthase inhibition on myocardial metabolism during moderate ischemiaAm J Physiol Heart Circ PhysiolYear: 2003284H2320H232412623779
41.. McGown CC,Brookes ZL. Beneficial effects of statins on the microcirculation during sepsis: the role of nitric oxideBr J AnaesthYear: 20079816317510.1093/bja/ael35817251210
42.. Merx MW,Flogel U,Stumpe T,Gödecke A,Decking UK,Schrader J. Myoglobin facilitates oxygen diffusionFASEB JYear: 2001151077107911292673
43.. Merx MW,Liehn EA,Graf J,van de Sandt A,Schaltenbrand M,Schrader J,Hanrath P,Weber C. Statin treatment after onset of sepsis in a murine model improves survivalCirculationYear: 200511211712410.1161/CIRCULATIONAHA.104.50219515998696
44.. Merx MW,Liehn EA,Janssens U,Lütticken R,Schrader J,Hanrath P,Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsisCirculationYear: 20041092560256510.1161/01.CIR.0000129774.09737.5B15123521
45.. Merx MW,Weber C. Sepsis and the heartCirculationYear: 200711679380210.1161/CIRCULATIONAHA.106.67835917698745
46.. Mozaffari MS, Baban B, Liu JY, Abebe W, Sullivan JC, El-Marakby A (2011) Mitochondrial complex I and NAD(P)H oxidase are major sources of exacerbated oxidative stress in pressure-overloaded ischemic-reperfused hearts. Basic Res Cardiol 106:287–297. doi:10.1007/s00395-011-0150-7
47.. Nussler AK,Bruckner UB,Vogt J,Radermacher P. Measuring end products of nitric oxide in vivoMethods EnyzmolYear: 2002359758310.1016/S0076-6879(02)59173-4
48.. Parrillo JE. Pathogenetic mechanisms of septic shockN Engl J MedYear: 19933281471147710.1056/NEJM1993052032820088479467
49.. Post H,Schulz R,Gres P,Heusch G. No involvement of nitric oxide in the limitation of beta -adrenergic inotropic responsiveness during ischemiaAm J Physiol Heart Circ PhysiolYear: 2001281H2392H239711709404
50.. Preiser JC,Zhang H,Vray B,Hrabak A,Vincent JL. Time course of inducible nitric oxide synthase activity following endotoxin administration in dogsNitric OxideYear: 2001520821110.1006/niox.2001.034211292370
51.. Rassaf T,Bryan NS,Kelm M,Feelisch M. Concomitant presence of N-nitroso and S-nitroso proteins in human plasmaFree Radic Biol MedYear: 2002331590159610.1016/S0891-5849(02)01183-812446216
52.. Rassaf T,Feelisch M,Kelm M. Circulating NO pool: assessment of nitrite and nitroso species in blood and tissuesFree Radic Biol MedYear: 20043641342210.1016/j.freeradbiomed.2003.11.01114975444
53.. Rassaf T,Poll LW,Brouzos P,Lauer T,Totzeck M,Kleinbongard P,Gharini P,Andersen K,Schulz R,Heusch G,Mödder U,Kelm M. Positive effects of nitric oxide on left ventricular function in humansEur Heart JYear: 2006271699170510.1093/eurheartj/ehl09616782717
54.. Reinartz M,Molojavyi A,Moellendorf S,Hohlfeld T,Heger J,Gödecke A. ß-Adrenergic signaling and response to pressure overload in transgenic mice with cardiac-specific overexpression of inducible NO synthaseNitric OxideYear: 201125112110.1016/j.niox.2011.04.00121645870
55.. Reinartz M,Ding Z,Flögel U,Gödecke A,Schrader J. Nitrosative stress leads to protein glutathiolation, increased S-nitrosation and up-regulation of peroxiredoxins in the heartJ Biol ChemYear: 2008283174401744910.1074/jbc.M80012620018426799
56.. Rudiger A, Singer M (2007) Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 35:1599–1608. doi:10.1097/01.CCM.0000266683.64081.02
57.. Schulz R,Dodge KL,Lopaschuk GD,Clanachan AS. Peroxynitrite impairs cardiac contractile function by decreasing cardiac efficiencyAm J PhysiolYear: 1997272H1212H12199087595
58.. Schulz R,Kelm M,Heusch G. Nitric oxide in myocardial ischemia/reperfusion injuryCardiovasc ResYear: 20046140241310.1016/j.cardiores.2003.09.01914962472
59.. Sirker A,Zhang M,Shah AM. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studiesBasic Res CardiolYear: 201110673574710.1007/s00395-011-0190-z21598086
60.. Staehr M,Madsen K,Vanhoutte PM,Hansen PB,Jensen BL. Disruption of COX-2 and eNOS does not confer protection from cardiovascular failure in lipopolysaccharide-treated conscious mice and isolated vascular ringsAm J Physiol Regul Integr Comp PhysiolYear: 2011301R412R42010.1152/ajpregu.00823.201021543636
61.. Stein B,Eschenhagen T,Rüdiger J,Scholz H,Förstermann U,Gath I. Increased expression of constitutive nitric oxide synthase III, but not inducible nitric oxide synthase II, in human heart failureJ Am Coll CardiolYear: 1998321179118610.1016/S0735-1097(98)00399-49809923
62.. Strunk V,Hahnenkamp K,Schneuing M,Fischer LG,Rich GF. Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilationAnesth AnalgYear: 20019268168710.1213/00000539-200103000-0002511226101
63.. Szelid Z,Pokreisz P,Liu X,Vermeersch P,Marsboom G,Gillijns H,Pellens M,Verbeken E,van de Werf F,Collen D,Janssens SP. Cardioselective nitric oxide synthase 3 gene transfer protects against myocardial reperfusion injuryBasic Res CardiolYear: 201010516917910.1007/s00395-009-0077-420020305
64.. Tavener SA,Kubes P. Cellular and molecular mechanisms underlying LPS-associated myocyte impairmentAm J Physiol Heart Circ PhysiolYear: 2006290H800H80610.1152/ajpheart.00701.200516172157
65.. Teng RJ,Wu TJ,Bisig CG,Eis A,Pritchard KA,Konduri GG. Nitrotyrosine impairs angiogenesis and uncouples eNOS activity of pulmonary artery endothelial cells isolated from developing sheep lungsPediatr ResYear: 20116911211710.1203/PDR.0b013e318204dcb821057377
66.. Thielmann M,Dörge H,Martin C,Belosjorow S,Schwanke U,van de Sand A,Konietzka I,Büchert A,Krüger A,Schulz R,Heusch G. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-α, and sphingosineCirc ResYear: 20029080781310.1161/01.RES.0000014451.75415.3611964374
67.. Thiemermann C,Szabó C,Mitchell JA,Vane JR. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxideProc Natl Acad Sci USAYear: 19939026727110.1073/pnas.90.1.2677678341
68.. Tiede K,Melchior-Becker A,Fischer JW. Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblastsBasic Res CardiolYear: 20101059910810.1007/s00395-009-0049-819701788
69.. van Faassen EE (2007) Radicals for life: the various forms of nitric oxide. Part V, pp 381–406. ISBN: 9780444522368
70.. van Faassen EE,Koeners MP,Joles JA,Vanin AF. Detection of basal NO production in rat tissues using iron-dithiocarbamate complexesNitric OxideYear: 20081827928610.1016/j.niox.2008.02.00318316042
71.. Vanin AF,Bevers LM,Mikoyan VD,Poltorakov AP,Kubrina LN,Van Faassen E. Reduction enhances yields of nitric oxide trapping by iron-diethyldithiocarbamate complex in biological systemsNitric OxideYear: 200716718110.1016/j.niox.2006.06.00916938475
72.. Vo PA,Lad B,Tomlinson JAP,Francis S,Ahluwalia A. Autoregulatory role of endothelium-derived nitric oxide (NO) on Lipopolysaccharide-induced vascular inducible NO synthase expression and functionJ Biol ChemYear: 20052807236724310.1074/jbc.M41131720015583003
73.. Wei XQ,Charles IG,Smith A,Ure J,Feng CJ,Huang FP,Xu DM,Muller W,Moncada S,Liew FY. Altered immune-responses in mice lacking inducible nitric-oxide synthaseNatureYear: 199537540841110.1038/375408a07539113
74.. Zhang T,Feng Q. Nitric oxide and calcium signaling regulate myocardial tumor necrosis factor-alpha expression and cardiac function in sepsisCan J Physiol PharmacolYear: 2010889210410.1139/Y09-09720237583
75.. Zhang T,Lu X,Li J,Chidiac P,Sims SM,Feng Q. Inhibition of Na/K-ATPase promotes myocardial tumor necrosis factor-alpha protein expression and cardiac dysfunction via calcium/mTOR signaling in endotoxemiaBasic Res CardiolYear: 201210725410.1007/s00395-012-0254-822351078
76.. Zhang YS,He L,Liu B,Li NS,Luo XJ,Hu CP,Ma QL,Zhang GG,Li YJ,Peng J. A novel pathway of NADPH oxidase/vascular peroxidase 1 in mediating oxidative injury following ischemia-reperfusionBasic Res CardiolYear: 201210726610.1007/s00395-012-0266-422476986

Figures

[Figure ID: Fig1]
Fig. 1 

NOS3 induces a hyperdynamic state and impairs survival in sepsis. a Prolonged survival in NOS3−/− mice. Survival time of septic NOS3−/− mice was profoundly increased as compared to septic WT mice. Unselective NOS inhibition with ETU diminished survival benefit in septic NOS3−/− mice and led to a slight improvement in septic WT mice. No deaths occurred in sham-operated mice (n = 12 per group). b Initial hyperdynamic state in septic WT mice. After recovery from anesthesia, cardiac output (CO) increased substantially in WT CLP mice followed by a rapid decline in CO. In contrast, NOS3−/− CLP and all sham-operated animals showed stable CO. CO was also stabilized after unselective NOS inhibition in WT and NOS3−/− mice (n = 12 per group)



[Figure ID: Fig2]
Fig. 2 

Impaired cardiac function and refractoriness to norepinephrine stimulation in septic WT but not in NOS3−/− mice in developing sepsis (in vivo measurements). Impaired cardiac function evident already at 6 h after sepsis induction with increased heart rate (a), decreased LVDP (b), dP/dtmax (c), and dP/dtmin (d) was observed in septic WT, with no difference being detected between septic NOS3−/− mice and non-septic animals. Septic WT mice respond to catecholamine application in early sepsis, which is likely due to increased heart rate (e), but remained refractory to norepinephrine stimulation at 12 h post CLP (fh) (*p < 0.05, **p < 0.01, ***p < 0.001 vs. WT at baseline; ##p < 0.01, ###p < 0.001 vs. WT mice; n = 4–10 per group; two-way ANOVA followed by Bonferroni’s post hoc test)



[Figure ID: Fig3]
Fig. 3 

NOS3 induces a drop in systemic vascular resistance. Diminished blood pressure in septic WT, while MAP remained stable in NOS3−/− (*p < 0.05, **p < 0.01 vs. WT at baseline; ##p < 0.01, ###p < 0.001 vs. WT mice; n = 4–10 per group; unpaired student’s t test) (a). Septic WT mice developed a progressive drop in systemic vascular resistance (b) (WT baseline vs. WT CLP 6 h: −34.6 %; WT baseline vs. WT CLP 12 h: −40.5 %). Systemic vascular resistance remained stable in NOS3−/− mice (NOS3−/− baseline vs. NOS3−/− CLP 6 h: −9.2 %, NOS3−/− baseline vs. NOS3−/− CLP 12 h: +1.3 %)



[Figure ID: Fig4]
Fig. 4 

NOS3 exacerbates decreased cardiac output in ongoing sepsis by direct myocardial depression. Ex vivo measurements (ac) from isolated hearts of baseline and septic WT and NOS3−/− mice revealed progressive myocardial dysfunction in septic WT mice, which reached the level of significance at 12 h after sepsis induction. NOS3−/− displayed a non-significant tendency towards impaired cardiac function (*p < 0.05, **p < 0.01, ***p < 0.001 vs. WT at baseline; #p < 0.05, ##p < 0.01, ###p < 0.001 vs. WT mice; n = 3–6 per group; two-way ANOVA followed by Bonferroni’s post hoc test)



[Figure ID: Fig5]
Fig. 5 

NOS3 impairs coronary flow reserve. Baseline coronary flow (CF) was increased solely in WT CLP mice. After NOS3 stimulation by bradykinin, coronary flow increased most substantially in WT CLP mice with no effect observed in NOS3−/− mice. Adenosine stimulation led to a maximum CF increase in all mice except WT CLP mice, in which CF response to adenosine was not greater than to bradykinin due to impaired coronary flow reserve (*p < 0.05 WT vs. WT CLP at baseline; ***p < 0.001 WT vs. WT CLP after application of bradykinin; #p < 0.05 WT CLP vs. NOS3−/− CLP at baseline, ###p < 0.001 WT CLP vs. NOS3−/− CLP after bradykinin application; n = 10 per group; two-way ANOVA followed by Bonferroni’s post hoc test)



[Figure ID: Fig6]
Fig. 6 

NOS3 contributes to bioactive NO pool in developing sepsis. Plasma nitrate levels (a) were increased 6 h after sepsis induction in WT and NOS3−/− mice (***p < 0.001 vs. baseline mice of the same genotype; ###p < 0.001 vs. WT mice; n = 10–16 per group; two-way ANOVA followed by Bonferroni’s post hoc test). Nitrate levels were lower in NOS3−/− compared to WT mice at baseline. Heart tissue nitrate levels (n = 4 per group) (b) and bioactive NO levels (c) (measured as MNIC yields per pmol wet heart tissue) were increased 6 h after sepsis induction in WT and NOS3−/− mice (**p < 0.05 vs. baseline mice of the same genotype; ***p < 0.001 vs. baseline mice of the same genotype; ###p < 0.001 vs. WT mice; n = 6–9 per group; two-way ANOVA followed by Bonferroni’s post hoc test), with a prominent increase in septic WT compared to NOS3−/−. NOx- and bioactive NO levels were comparable between both strains at baseline



Tables
[TableWrap ID: Tab1] Table 1 

Inflammatory response in developing sepsis


Parameter WT NOS3−/−
BL CLP 6 h CLP 12 h BL CLP 6 h CLP 12 h
Blood cell count (103/µl)
 White blood cells 5.17 ± 1.64 2.11 ± 0.60*** 1.31 ± 0.42*** 3.74 ± 0.67## 2.60 ± 0.75** 1.86 ± 0 51***
 Granulocytes 1.17 ± 0.29 1.53 ± 0.51 0.88 ± 0.27 1.18 ± 0.17 1.78 ± 0.58** 1.04 ± 0.26
 Monocytes 0.38 ± 0.17 0.13 ± 0.12*** 0.12 ± 0.04*** 0.29 ± 0.06 0.14 ± 0.05** 0.16 ± 0.07**
 Lymphocytes 3.62 ± 1.20 0.73 ± 0.32*** 0.52 ± 0.13*** 2.28 ± 0.49### 0.68 ± 0.19*** 0.63 ± 0.29***
Myocardial histology (cells/mm2)
 Granulocytes 755 ± 134 1,778 ± 90*** 2,362 ± 78*** 566 ± 90 1,559 ± 238*** 1,620 ± 206***
 Monocytes 896 ± 87 2,297 ± 324*** 2,238 ± 229*** 645 ± 149 1,538 ± 265***,### 1,668 ± 297***
 Lymphocytes 439 ± 64 1,375 ± 247*** 1,574 ± 411*** 318 ± 82 1,272 ± 379*** 1,325 ± 233***
Myocardial gene expression
 IL-6 1.0 81.0*** 16.7*** 1.1 79.1*** 6.7
 TNF-α 1.0 6.5*** 1.4 1.4 6.7*** 4.0

Mean ± SD; blood cell count n = 6–13 per group; myocardial histology n = 4–8 per group; myocardial gene expression n = 3 per group

Two-way ANOVA followed by Bonferroni posthoc test; myocardial gene expression was analyzed by REST 2009 software (Quiagen)

p < 0.05 vs. baseline of the same genotype

** p < 0.01 vs. baseline of the same genotype

*** p < 0.001 vs. baseline of the same genotype

## p < 0.01 vs. WT mice

### p < 0.001 vs. WT mice



Article Categories:
  • Original Contribution

Keywords: Keywords Sepsis, Septic cardiomyopathy, Nitric oxide, NOS3.

Previous Document:  Ilex paraguariensis (yerba mate) improves endocrine and metabolic disorders in obese rats primed by ...
Next Document:  Clinical, dermoscopic and immunohistochemical assessment of actinic keratoses and evaluation of the ...